A comparison of the efficacy and safety of 0.025% and 0.05% tretinoin cream in the treatment of acanthosis nigricans

Phase 3

• Conditions: Acanthosis nigricans; Acanthosis nigricans, tretinoin

• Registration Number: TCTR20201124001
• Lead Sponsor: Faculty of Medicine, Srinakhariwirot University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-11-24
• Study Completion: 2021-04-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

The participants aged over 18 years with a diagnosis of acanthosis nigricans

Exclusion Criteria

- Vulnerable skin diseases
- Infectious skin diseases
- Other recent diseases involving the neck
- Other serious medical disorders e.g. DM, liver disease
- Any patients having received other therapies for up to 4 weeks prior to enrollment, such as corticosteroids, vitamin D, trichloroacetic acid (TCA), or other chemical peeling agents.
- Photosensitive skin
- Immunocompromised host
- Pregnancy and lactation
- Receiving oral retinoids
- Neck tattoo

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
the efficacy week 0, 2, 4 and week 8 the Mexameter MX18

Secondary Outcome Measures

Name	Time	Method
The efficacy week 0,2,4,8 using the investigator’s global evaluation (IGE) ,Side effect week 0,2,4,8 cutaneous irritation grading scales